Mentari, InMed Merge In Deal Backed By $290M Funding
InMed Pharmaceuticals Inc. on Tuesday announced plans to merge with migraine prevention drugmaker Mentari Therapeutics Inc. in an all-stock deal that is backed by a $290 million private placement and was...To view the full article, register now.
Already a subscriber? Click here to view full article